Question special

As we wrap up this discussion on sepsis with a focus on the enlightening recent clinical trials on EGDT, I’d like to thank the authors and experts for participating, and the NEJM Group and Medstro for organizing this discussion. I’d also like to invite the authors and experts to offer any closing remarks about any topic you deem important (perhaps one that wasn’t covered adequately).